MODERATOR(S)
Charles Simone, MD, FASTRO - New York Proton Center and Memorial Sloan Kettering Cancer Center
Jeffrey Bradley, MD, FASTRO - University of Pennsylvania
session DESCRIPTION
Please note: The abstracts listed below will not be presented by the authors during this session. Instead, a designated discussant will highlight and discuss key findings and takeaways from these abstracts.
Credits
| AMA PRA Category 1 Credits: | 0.50 |
| CAMPEP Credits: | 0.50 |
| MDCB Credits: | 0.50 |
Presentations
-
09:15am - 09:20am ET
-
09:20am - 09:25am ET
NRG-CC009: A Phase III Trial of Stereotactic Radiosurgery (SRS) vs. Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Brain Metastases from Small Cell Lung Cancer (SCLC)
Speaker: Chad Rusthoven, MD - University of Colorado School of Medicine, Aurora -
09:25am - 09:30am ET
A Prospective, Randomized Controlled Study on the Time Window of Radiotherapy Combined with Targeted Therapy for Primary Tumor in Stage IV NSCLC
Speaker: Feng Jin, BS - Affiliated Hospital of Guizhou Medical University, Guiyang -
09:30am - 09:35am ET
Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT): Long-Term Outcomes
Speaker: Caroline Oska, MD - Montefiore Einstein Comprehensive Cancer Center, Bronx -
09:35am - 09:40am ET
Chemoradiotherapy (CRT) Followed By Consolidation Durvalumab (D) In Patients (pts) with Resectable or Borderline Resectable Stage IIB-IIIB NSCLC Who Become Unresectable during Neoadjuvant Treatment (Tx): Results from the Phase 2 MDT-Bridge Study
Speaker: Andrea Filippi, MD - Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan -
09:40am - 09:45am ET
Six-Year Overall Survival of Nivolumab Following Stereotactic Ablative Radiotherapy in Early-Stage Non-Small Cell Lung Cancer: Randomized I-SABR Trial
Speaker: Joe Chang, MD, PhD, MS, FASTRO - MD Anderson Cancer Center, Houston